Neoadjuvant chemotherapy combined with antiangiogenic therapy and immune checkpoint inhibitors for the treatment of locally advanced gastric cancer: a real - world retrospective cohort study
The combination of neoadjuvant chemotherapy, anti-angiogenic therapy, and ICIs has proven effective in treating LAGC patients, achieving high pCR rates and favorable survival outcomes while maintaining an acceptable safety profile.
Authors
- Changhua Zhuo (ORCID: https://orcid.org/0000-0002-5900-9048)
- Wan‐Ting Huang (ORCID: https://orcid.org/0000-0001-6442-3713)
- Zengqing Guo (ORCID: https://orcid.org/0000-0002-9645-5186)
- Bijuan Chen (ORCID: https://orcid.org/0000-0002-9817-7220)
- Zhouwei Zhan (ORCID: https://orcid.org/0000-0002-3657-6365)
- Haiting Chen (ORCID: https://orcid.org/0000-0002-3349-6896)
- Xiaohuan Ma (ORCID: https://orcid.org/0000-0002-5839-5207)
- Yu Chen (ORCID: https://orcid.org/0000-0003-0277-6614)
- Shaohua Xu (ORCID: https://orcid.org/0000-0002-7004-5955)
- Ruyu Lin
- Xuanping Lin
Institutions
- Fujian Medical University (CN)
- Fujian Provincial Cancer Hospital (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-02-04
- DOI
- https://doi.org/10.3389/fimmu.2025.1518217
- Citations
- 2
- Primary Topic
- Gastric Cancer Management and Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 3.04
Funders
- National Natural Science Foundation of China
- Natural Science Foundation of Fujian Province
- Fujian Provincial Health Commission
- Fonds Spéciaux de Recherche